Could cause temporary or reversible harm; serious harm is unlikely.
CGMP Deviations: N-Nitroso Desloratadine impurity result exceeded the acceptable intake limit.
| Brand name | DESLORATADINE |
| Generic name | DESLORATADINE |
| Active ingredient(s) | DESLORATADINE |
| Distributed by / for | Lupin Pharmaceuticals, Inc. Baltimore, Maryland 21202 |
| NDC | 68180-153-01 |
| Full product label | Desloratadine Tablets USP 5mg a) 100 count (NDC 68180-153-01) and b) 500 count (NDC 68180-153-02) bottles, Rx Only, Manufactured for: Lupin Pharmaceuticals, Inc. Baltimore, Maryland 21202. |
| Recalling firm | Lupin Pharmaceuticals Inc. |
| Distribution | Product was distributed nationwide. |
| Quantity | 100=29,184 bottles; 500=2922 bottles |
| Recall initiated | 2023-12-20 |
| Report date | 2024-01-17 |
| Recall completed | 2025-04-04 |
| Recall number | D-0221-2024 |
| Classification | Class II |
| FDA status | Terminated |
| Origin on file | Baltimore MD United States |
Source: U.S. FDA enforcement database (openFDA). Look this up on the official FDA recalls site ↗